Sutent Mechanism
Nov. 24, 2024
Molecular basis for sunitinib efficacy and future clinical development | Nature Reviews Drug Discovery The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma | British Journal of Cancer Mechanisms of action of sunitinib (from Rini et al., with the... | Download Scientific Diagram Sutent Mechanism